AstraZeneca's weight loss pill received underwhelming reviews, causing its share price to drop by 8%. Additionally, the company's China unit faces an insurance fraud case, with dozens of executives under investigation. AstraZeneca is cooperating with Chinese authorities amidst these challenges.